AveXis Stock Price, News & Analysis (NASDAQ:AVXS)

$121.47 +1.94 (+1.62 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$121.47
Today's Range$115.11 - $121.69
52-Week Range$54.11 - $128.00
Volume182,812 shs
Average Volume447,493 shs
Market Capitalization$4.36 billion
P/E Ratio-21.77
Dividend YieldN/A
Beta2.1

About AveXis (NASDAQ:AVXS)

AveXis logoAveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

Receive AVXS News and Ratings via Email

Sign-up to receive the latest news and ratings for AVXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVXS
CUSIPN/A
Phone847-572-8280

Debt

Debt-to-Equity RatioN/A
Current Ratio13.96%
Quick Ratio13.96%

Price-To-Earnings

Trailing P/E Ratio-21.7688172043011
Forward P/E Ratio-19.50
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$8.89 per share
Price / Book13.66

Profitability

Trailing EPS($5.58)
Net Income$-83,010,000.00
Net MarginsN/A
Return on Equity-49.27%
Return on Assets-45.59%

Miscellaneous

Employees70
Outstanding Shares36,480,000

AveXis (NASDAQ:AVXS) Frequently Asked Questions

What is AveXis' stock symbol?

AveXis trades on the NASDAQ under the ticker symbol "AVXS."

How were AveXis' earnings last quarter?

AveXis Inc (NASDAQ:AVXS) posted its earnings results on Thursday, November, 9th. The company reported ($1.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.48) by $0.04. During the same quarter in the prior year, the company earned ($0.87) earnings per share. View AveXis' Earnings History.

When will AveXis make its next earnings announcement?

AveXis is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for AveXis.

Where is AveXis' stock going? Where will AveXis' stock price be in 2018?

18 analysts have issued 12 month price objectives for AveXis' shares. Their forecasts range from $52.00 to $152.00. On average, they anticipate AveXis' share price to reach $118.94 in the next twelve months. View Analyst Ratings for AveXis.

What are Wall Street analysts saying about AveXis stock?

Here are some recent quotes from research analysts about AveXis stock:

  • 1. Mizuho analysts commented, "We expect a pre-BLA meeting in 2Q/3Q18, and potential regulatory approval in 2019 for type 1 SMA. We also see additional upside for AVXS-101 in SMA type 2 patients. KeyPoints Gene therapy is coming of age. After years of advancements and discovery in the field of gene therapy, we believe a number of companies are on the cusp of gaining approval for these novel one-time treatments. We see strong potential for leading candidate products and take confidence from the recent unanimous FDA approval of Spark’s (ONCE, Buy, $79 PT) Luxturna. A significant opportunity for gene therapy in the treatment of SMA. With approximately 60% of the incident SMA population affected by type 1 and limited treatment options, AveXis’ lead product candidate AVXS-101 could have a substantial impact. Given strong data from a recent phase 1 trial, we believe AVXS-101 could capture a significant market share in SMA type 1." (2/12/2018)
  • 2. According to Zacks Investment Research, "AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. " (1/9/2018)
  • 3. Chardan Capital analysts commented, "We would encourage buying on any AVXS weakness today, on the potential that the market may have understandably misunderstood what could be an atypical but stepped up process in terms of filing timelines for AVXS-101 in SMA type 1. Our take: Our base case (see our 15 June 2017 note) of a filing after pivotal STR1VE (NCT03306277) phase III data seems to have been improved upon. There are reasons to believe AveXis could file AVXS-101 by 3Q18, with a blue skies" scenario involving AVXS-101 approval by end-2018 or early-2019. We note AveXis’ appropriately non-promotional commentary when executing its duties in communicating status of important regulatory matters to the market." (1/5/2018)
  • 4. Jefferies Group LLC analysts commented, "Final data from AVXS-101 in SMA T1 reported that all pts in both cohorts were event free at 13.6 mo of age compared to 25% expected via natural history, the primary EP. Motor milestones were achieved with 9 pts sitting ' 5 secs and 2 pts walking independently. We have lowered our EU T1 risk adj to 15% and began including SMA T2 into our valuation with a 75% risk adj. We reiterate our Buy rating and raise our PT to $92." (3/17/2017)
  • 5. Goldman Sachs Group Inc analysts commented, "AVXS reported compelling gene therapy AVXS-101 Ph1 final results in spinal muscular atrophy (SMA, genetic neuromuscular disorder) Type I for all patients >13.6 months of age. The data continues to impress ' event-free survival (EFS, death or permanent ventilation) remains 100% in the 12 patients in the high dose therapeutic and notably, in the 3 non-therapeutic cohort as of 1/20. These results are remarkably better than the disease natural history of SMA Type I that suggests 25% EFS at 13.6 months. CHOP INTEND (motor function) and milestone improvements remain intact, with mean increase from baseline of +24.7 (vs. +24.8 prior) in the therapeutic dose vs. -10.5/yr per natural history. 11 (92%) patients are sitting unassisted (by definition, SMA Type I patients never sit unassisted), 9 (75%) rolling over, 2 (17%) standing alone and 2 (17%) walking independently, in line with prior 3m data. On the safety front, SAEs remain restricted to prior asymptomatic liver enzyme elevations which resolved with steroids. We look to: (1) the May 1 FDA meeting (vs. Mar) to discuss the manufacturing (CMC) outlook and June update post receipt of minutes; and (2) an end-of-Ph1 meeting with the FDA in 2Q/3Q to discuss a potential accelerated approval, which would provide upside to our estimates (we assume a 2020 launch on Ph3 data, GSe peak sales of $927mn)." (3/17/2017)

Who are some of AveXis' key competitors?

Who are AveXis' key executives?

AveXis' management team includes the folowing people:

  • Daniel G. Welch, Independent Chairman of the Board (Age 59)
  • Sean Patrick Nolan, President, Chief Executive Officer, Director (Age 49)
  • Phillip B. Donenberg, Principal Financial Officer, Senior Vice President, Principal Accounting Officer (Age 57)
  • Lori J. Smith, Chief Human Resource Officer, Senior Vice President (Age 53)
  • Michael Johannesen, Senior Vice President, Chief Compliance Officer, General Counsel (Age 51)
  • Andrew F. Knudten, Senior Vice President - Manufacturing and Supply Chain (Age 49)
  • James J. L'Italien Ph.D., Senior Vice President - Chief Regulatory and Quality Officer (Age 64)
  • Rick Modi, Senior Vice President, Chief Business Officer (Age 48)
  • Sukumar Nagendran, Senior Vice President and Chief Medical Officer (Age 50)
  • R. A. Session II, Senior Vice President - Corporate Strategy and Project Management (Age 38)

When did AveXis IPO?

(AVXS) raised $86 million in an IPO on Thursday, February 11th 2016. The company issued 4,300,000 shares at $19.00-$21.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.

Who owns AveXis stock?

AveXis' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.69%), Perceptive Advisors LLC (1.32%), Viking Global Investors LP (1.31%), Alliancebernstein L.P. (1.28%), Franklin Resources Inc. (0.98%) and Eagle Asset Management Inc. (0.97%). Company insiders that own AveXis stock include Andrew F Knudten, Brian K Kaspar, James J Litalien, Paul B Manning and Sukumar Nagendran. View Institutional Ownership Trends for AveXis.

Who sold AveXis stock? Who is selling AveXis stock?

AveXis' stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, RTW Investments LP, Viking Global Investors LP, BlackRock Inc., Spark Investment Management LLC, Goldman Sachs Group Inc., Alliancebernstein L.P. and Franklin Resources Inc.. Company insiders that have sold AveXis company stock in the last year include Andrew F Knudten, Brian K Kaspar, James J Litalien and Sukumar Nagendran. View Insider Buying and Selling for AveXis.

Who bought AveXis stock? Who is buying AveXis stock?

AveXis' stock was purchased by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Eagle Asset Management Inc., Deutsche Bank AG, Element Capital Management LLC, Tekla Capital Management LLC, Senzar Asset Management LLC, Artal Group S.A. and Eaton Vance Management. View Insider Buying and Selling for AveXis.

How do I buy AveXis stock?

Shares of AveXis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AveXis' stock price today?

One share of AveXis stock can currently be purchased for approximately $121.47.

How big of a company is AveXis?

AveXis has a market capitalization of $4.36 billion. The company earns $-83,010,000.00 in net income (profit) each year or ($5.58) on an earnings per share basis. AveXis employs 70 workers across the globe.

How can I contact AveXis?

AveXis' mailing address is 2275 HALF DAY ROAD SUIT 200, BANNOCKBURN IL, 60015. The company can be reached via phone at 847-572-8280 or via email at [email protected]


MarketBeat Community Rating for AveXis (AVXS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  357
MarketBeat's community ratings are surveys of what our community members think about AveXis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AveXis (NASDAQ:AVXS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.652.632.75
Ratings Breakdown: 2 Sell Rating(s)
2 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $118.94$113.53$109.88$103.55
Price Target Upside: 2.05% upside8.26% upside14.70% upside6.77% upside

AveXis (NASDAQ:AVXS) Consensus Price Target History

Price Target History for AveXis (NASDAQ:AVXS)

AveXis (NASDAQ:AVXS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/20/2018Sanford C. BernsteinReiterated RatingOutperform$110.00 -> $144.00HighView Rating Details
2/12/2018MizuhoInitiated CoverageBuy -> Buy$147.00MediumView Rating Details
2/9/2018BarclaysBoost Price TargetOverweight -> Overweight$124.00 -> $152.00MediumView Rating Details
1/30/2018William BlairReiterated RatingBuyLowView Rating Details
1/18/2018BMO Capital MarketsReiterated RatingBuy$150.00HighView Rating Details
1/17/2018Credit Suisse GroupInitiated CoverageOutperform -> Outperform$134.00HighView Rating Details
1/9/2018Royal Bank of CanadaReiterated RatingHold$92.00MediumView Rating Details
1/5/2018Canaccord GenuitySet Price TargetHold$110.00HighView Rating Details
1/5/2018Chardan CapitalReiterated RatingBuy$135.00HighView Rating Details
1/5/2018Morgan StanleySet Price TargetBuy$120.00HighView Rating Details
1/5/2018CitigroupSet Price TargetPositive -> Buy$132.00HighView Rating Details
11/10/2017Bank of AmericaLower Price TargetBuy$115.00 -> $112.00N/AView Rating Details
10/12/2017Jefferies GroupBoost Price TargetBuy$118.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingBuy -> Buy$130.00N/AView Rating Details
9/29/2017Wells Fargo & CoReiterated RatingOutperformHighView Rating Details
8/29/2017InstinetInitiated CoverageReduce -> Reduce$52.00LowView Rating Details
8/28/2017NomuraInitiated CoverageReduce$52.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$120.00MediumView Rating Details
11/14/2016Stifel NicolausInitiated CoverageHold$65.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

AveXis (NASDAQ:AVXS) Earnings History and Estimates Chart

Earnings by Quarter for AveXis (NASDAQ:AVXS)

AveXis (NASDAQ AVXS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($1.64)N/AView Earnings Details
11/9/2017Q3 2017($1.48)($1.52)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.97)($2.07)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.95)($1.07)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.77)($0.92)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.70)($0.87)ViewListenView Earnings Details
8/11/2016Q216($0.77)($0.68)ViewListenView Earnings Details
5/12/2016Q1($0.35)($1.24)ViewListenView Earnings Details
3/18/2016Q4 2015($0.42)($1.82)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AveXis (NASDAQ:AVXS) Earnings Estimates

2018 EPS Consensus Estimate: ($6.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.54)($1.54)($1.54)
Q2 20181($1.56)($1.56)($1.56)
Q3 20181($1.58)($1.58)($1.58)
Q4 20181($1.59)($1.59)($1.59)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for AveXis (NASDAQ:AVXS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AveXis (NASDAQ AVXS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 82.66%
Insider Trades by Quarter for AveXis (NASDAQ:AVXS)
Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

AveXis (NASDAQ AVXS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2018Andrew F KnudtenVPSell2,000$118.13$236,260.007,000View SEC Filing  
2/1/2018Brian K KasparInsiderSell15,000$118.07$1,771,050.001,792,147View SEC Filing  
1/16/2018James J LitalienVPSell5,000$106.52$532,600.00View SEC Filing  
1/2/2018Brian K KasparInsiderSell15,000$109.75$1,646,250.001,808,386View SEC Filing  
1/2/2018Sukumar NagendranVPSell1,780$109.72$195,301.601,780View SEC Filing  
12/4/2017Andrew F KnudtenVPSell2,000$94.48$188,960.007,000View SEC Filing  
12/1/2017Brian K KasparInsiderSell15,000$94.73$1,420,950.001,826,502View SEC Filing  
12/1/2017Sukumar NagendranVPSell1,780$94.77$168,690.601,780View SEC Filing  
11/1/2017Brian K KasparInsiderSell15,000$101.23$1,518,450.001,841,019View SEC Filing  
11/1/2017Sukumar NagendranVPSell1,780$101.26$180,242.801,780View SEC Filing  
10/9/2017Brian K KasparInsiderSell15,000$101.46$1,521,900.00View SEC Filing  
10/2/2017Sukumar NagendranVPSell1,780$97.25$173,105.001,780View SEC Filing  
9/1/2017Sukumar NagendranVPSell1,780$93.25$165,985.001,780View SEC Filing  
8/1/2017Sukumar NagendranVPSell1,780$91.52$162,905.601,780View SEC Filing  
7/3/2017Sukumar NagendranVPSell1,780$81.88$145,746.401,780View SEC Filing  
6/1/2017Sukumar NagendranVPSell1,780$70.91$126,219.801,780View SEC Filing  
5/1/2017Sukumar NagendranVPSell1,780$81.39$144,874.201,780View SEC Filing  
4/3/2017Sukumar NagendranVPSell1,781$76.13$135,587.531,781View SEC Filing  
9/13/2016Paul B ManningInsiderSell289,855$34.50$9,999,997.50View SEC Filing  
2/17/2016Bong Y KohDirectorBuy100,000$20.00$2,000,000.00View SEC Filing  
2/17/2016James E FlynnInsiderBuy750,317$19.47$14,608,671.99View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AveXis (NASDAQ AVXS) News Headlines

Source:
DateHeadline
AveXis (AVXS) to Release Earnings on TuesdayAveXis (AVXS) to Release Earnings on Tuesday
www.americanbankingnews.com - February 22 at 8:16 PM
AveXis (AVXS) Given Outperform Rating at Sanford C. BernsteinAveXis (AVXS) Given Outperform Rating at Sanford C. Bernstein
www.americanbankingnews.com - February 20 at 4:52 PM
AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating ResultsAveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results
finance.yahoo.com - February 20 at 9:16 AM
AveXis Sees Unusually High Options Volume (AVXS)AveXis Sees Unusually High Options Volume (AVXS)
www.americanbankingnews.com - February 20 at 6:56 AM
Mizuho Begins Coverage on AveXis (AVXS)Mizuho Begins Coverage on AveXis (AVXS)
www.americanbankingnews.com - February 12 at 8:28 PM
AveXis (AVXS) Given New $152.00 Price Target at BarclaysAveXis (AVXS) Given New $152.00 Price Target at Barclays
www.americanbankingnews.com - February 9 at 8:24 PM
Why A Gene Therapy Pioneer Is Raising Concerns About Treatments He ChampionedWhy A Gene Therapy Pioneer Is Raising Concerns About Treatments He Championed
finance.yahoo.com - February 8 at 9:03 AM
AveXis Inc (AVXS) VP Sells $236,260.00 in StockAveXis Inc (AVXS) VP Sells $236,260.00 in Stock
www.americanbankingnews.com - February 5 at 7:02 PM
AveXis Inc (AVXS) Insider Sells $1,771,050.00 in StockAveXis Inc (AVXS) Insider Sells $1,771,050.00 in Stock
www.americanbankingnews.com - February 5 at 6:26 PM
AveXis Inc (AVXS) Receives Consensus Rating of "Buy" from AnalystsAveXis Inc (AVXS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 2 at 1:59 PM
Q1 2018 Earnings Estimate for AveXis Inc (AVXS) Issued By Jefferies GroupQ1 2018 Earnings Estimate for AveXis Inc (AVXS) Issued By Jefferies Group
www.americanbankingnews.com - February 2 at 9:30 AM
BRIEF-Avexis To Initiate Screening For Remaining Patients In Pivotal Trial Of AVXS-101BRIEF-Avexis To Initiate Screening For Remaining Patients In Pivotal Trial Of AVXS-101
www.reuters.com - January 31 at 9:11 AM
AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three PatientsAveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients
finance.yahoo.com - January 30 at 4:37 PM
AveXis (AVXS) "Buy" Rating Reiterated at William BlairAveXis' (AVXS) "Buy" Rating Reiterated at William Blair
www.americanbankingnews.com - January 30 at 4:18 PM
Rare disease drug is driving Biogen earnings, but for how long?Rare disease drug is driving Biogen earnings, but for how long?
www.marketwatch.com - January 27 at 4:35 PM
-$1.51 Earnings Per Share Expected for AveXis Inc (AVXS) This Quarter-$1.51 Earnings Per Share Expected for AveXis Inc (AVXS) This Quarter
www.americanbankingnews.com - January 26 at 11:06 AM
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesAveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 22 at 5:39 PM
AveXis (AVXS) "Buy" Rating Reiterated at BMO Capital MarketsAveXis' (AVXS) "Buy" Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - January 21 at 11:06 PM
James J. Litalien Sells 5,000 Shares of AveXis Inc (AVXS) StockJames J. Litalien Sells 5,000 Shares of AveXis Inc (AVXS) Stock
www.americanbankingnews.com - January 18 at 7:00 PM
AveXis (AVXS) Coverage Initiated by Analysts at Credit Suisse GroupAveXis (AVXS) Coverage Initiated by Analysts at Credit Suisse Group
www.americanbankingnews.com - January 17 at 5:24 PM
AveXis (AVXS) Reports Expanded Clinical Development Program for AVXS-101 in Spinal Muscular AtrophyAveXis (AVXS) Reports Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy
www.streetinsider.com - January 17 at 10:58 AM
AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy - GlobeNewswire (press release)AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy - GlobeNewswire (press release)
globenewswire.com - January 16 at 3:56 PM
AveXis Announces Proposed Public Offering of Common StockAveXis Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 16 at 11:00 AM
AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular AtrophyAveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy
finance.yahoo.com - January 16 at 11:00 AM
AveXis shares drop 6% on companys plans to offer up to $400 mln shares in public offeringAveXis shares drop 6% on company's plans to offer up to $400 mln shares in public offering
finance.yahoo.com - January 16 at 11:00 AM
Will 2018 Be Ionis Pharmaceuticals, Inc.s Best Year Yet?Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?
finance.yahoo.com - January 13 at 3:53 PM
AveXis (AVXS) Raised to "Hold" at Zacks Investment ResearchAveXis (AVXS) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 9 at 5:40 PM
Regenxbio (RGNX), AveXis (AVXS) Expand Relationship through Amended License Agreement for Development and ... - StreetInsider.comRegenxbio (RGNX), AveXis (AVXS) Expand Relationship through Amended License Agreement for Development and ... - StreetInsider.com
www.streetinsider.com - January 9 at 4:00 PM
Avexis Joins Rank Of Stocks With RS Ratings Over 90Avexis Joins Rank Of Stocks With RS Ratings Over 90
finance.yahoo.com - January 9 at 10:51 AM
Zacks: Analysts Expect AveXis Inc (AVXS) Will Announce Earnings of -$1.51 Per ShareZacks: Analysts Expect AveXis Inc (AVXS) Will Announce Earnings of -$1.51 Per Share
www.americanbankingnews.com - January 9 at 7:32 AM
AveXis (AVXS) Earns "Buy" Rating from BMO Capital MarketsAveXis (AVXS) Earns "Buy" Rating from BMO Capital Markets
www.americanbankingnews.com - January 9 at 12:52 AM
AveXis Inc (AVXS) Expected to Earn FY2022 Earnings of $9.30 Per ShareAveXis Inc (AVXS) Expected to Earn FY2022 Earnings of $9.30 Per Share
www.americanbankingnews.com - January 8 at 9:40 PM
AveXis (AVXS) PT Set at $132.00 by CitigroupAveXis (AVXS) PT Set at $132.00 by Citigroup
www.americanbankingnews.com - January 7 at 7:36 AM
AveXis (AVXS) Given a $110.00 Price Target by Canaccord Genuity AnalystsAveXis (AVXS) Given a $110.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - January 6 at 10:22 AM
BRIEF-Avexis Inc Plans To Request A Pre-BLA Meeting For AVXS-101 In Q2BRIEF-Avexis Inc Plans To Request A Pre-BLA Meeting For AVXS-101 In Q2
www.reuters.com - January 5 at 4:04 PM
AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1
finance.yahoo.com - January 5 at 4:04 PM
AveXis shares down more than 7% after FDA newsAveXis shares down more than 7% after FDA news
finance.yahoo.com - January 5 at 4:04 PM
AveXis (AVXS) Rating Reiterated by Chardan CapitalAveXis (AVXS) Rating Reiterated by Chardan Capital
www.americanbankingnews.com - January 5 at 1:32 PM
AveXis (AVXS) Given a $120.00 Price Target at Morgan StanleyAveXis (AVXS) Given a $120.00 Price Target at Morgan Stanley
www.americanbankingnews.com - January 5 at 10:22 AM
UBS Group Analysts Give AveXis (AVXS) a $122.00 Price TargetUBS Group Analysts Give AveXis (AVXS) a $122.00 Price Target
www.americanbankingnews.com - January 5 at 9:38 AM
Insider Selling: AveXis Inc (AVXS) VP Sells 1,780 Shares of StockInsider Selling: AveXis Inc (AVXS) VP Sells 1,780 Shares of Stock
www.americanbankingnews.com - January 4 at 7:56 PM
AveXis Inc (AVXS) Insider Brian K. Kaspar Sells 15,000 SharesAveXis Inc (AVXS) Insider Brian K. Kaspar Sells 15,000 Shares
www.americanbankingnews.com - January 4 at 7:02 PM
AveXis could be lifted by rival Spark Therapeutics pricing scheme for gene therapy: RBCAveXis could be lifted by rival Spark Therapeutics' pricing scheme for gene therapy: RBC
finance.yahoo.com - January 3 at 3:59 PM
Commit To Purchase AveXis At $85, Earn 11% Annualized Using OptionsCommit To Purchase AveXis At $85, Earn 11% Annualized Using Options
www.nasdaq.com - December 29 at 3:56 PM
Top 10 Biopharma Events Kicking Off 2018Top 10 Biopharma Events Kicking Off 2018
247wallst.com - December 28 at 2:31 PM
 Analysts Anticipate AveXis Inc (AVXS) Will Post Earnings of -$1.51 Per Share Analysts Anticipate AveXis Inc (AVXS) Will Post Earnings of -$1.51 Per Share
www.americanbankingnews.com - December 23 at 9:20 PM
AveXis (AVXS) Lifted to "Hold" at BidaskClubAveXis (AVXS) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - December 22 at 11:28 PM
Canaccord Genuity Reiterates $110.00 Price Target for AveXis (AVXS)Canaccord Genuity Reiterates $110.00 Price Target for AveXis (AVXS)
www.americanbankingnews.com - December 21 at 10:00 AM
BidaskClub Lowers AveXis (AVXS) to SellBidaskClub Lowers AveXis (AVXS) to Sell
www.americanbankingnews.com - December 17 at 7:20 AM
AveXis (AVXS) Reports Plan to Commence Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101AveXis (AVXS) Reports Plan to Commence Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101
www.streetinsider.com - December 15 at 11:30 AM

SEC Filings

AveXis (NASDAQ:AVXS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AveXis (NASDAQ:AVXS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AveXis (NASDAQ AVXS) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.